PLATFORM Claros is currently focused on urological maladies, specifically those associated with the prostate. Relying on an un-paralleled ease of use, the system is designed to operate in near-patient settings, such as a physician's office. The capability of the Claros platform to perform multiple tests simultaneously (multiplexing) can be exploited to include the analysis of existing and novel biomarkers to improve the overall quality of care in urology. The capabilities of the Claros technology inherently allows for applications beyond urology, especially for decentralized clinical testing. The platform nature of the Claros technology affords the opportunity to pursue several decentralized testing applications. These additional applications include but are not limited to female healthcare, metabolic disorders, thyroid disorders, ovulation, heart disease, infectious diseases and cancer. In addition, the Claros device can facilitate creation of diagnostic / therapeutic combinations in order to improve access for the patient to adequate therapies and monitor the use of therapeutics. Claros has validated its core technology in the laboratory with qualitative and quantitative detection of infectious diseases, including HIV, herpes simplex 2, hepatitis C, and hepatitis B (surface antigen). The Claros system has the capability of dramatically increasing the range of possible locations where diagnostic testing can be provided. As such, a strong opportunity exists to utilize the technology in extreme resource-poor settings to improve global health. In considering our business development objectives, we will continue to diligently source and evaluate new biomarkers, diagnostic technologies and opportunities for in-licensing and collaboration with clinicians, researchers and companies in an effort to optimize our technology offering.